CANCERS BRONCHIQUES NON A PETITES CELLULES : RADIOCHIMIOTHERAPIE (Stades III essentiellement) |
|
|
Référence |
Méthodologie |
Critère de jugement |
Nombre d'essais |
Nombre de patients |
Résultat |
|
Chimiothérapie ajoutée à la radiothérapie
radicale |
|||||
|
Collaborative
Group, 1995 (1) |
MADI |
Survie globale |
22 |
3033 |
S HR = 0,87 |
|
Marino, 1995 (2) |
MARSL |
Survie à 1 et 2 ans |
14 |
1887 |
S (cisplatine) HR = 0,76 (IC 95 % 0,6 – 0,9) et 0,70 (0,5 – 0,9) |
|
Pritchard,
1996 (3) |
MAI |
Survie à 1, 2, 3 ans |
14 |
2589 |
S RR = 0,88 (0,80 – 0,96), 0,87 (0,81 – 0,94), 0,83 (0,77 – 0,90) |
|
Auperin, 2006 (4) |
MADI |
Survie globale |
9 |
1754 |
S HR = 0,89 (0,81 – 0,98) |
|
Bozcuk, 2010 (5) |
MAI |
Survie à 2 et 3 ans |
13 |
2776 |
S RR = 0,91 (IC 95 % 0,87 – 0,94) et 0,94 (0,92 – 0,97) |
|
Chimiothérapie d'induction avant
radiothérapie radicale |
|||||
|
Sculier, 2001 (6) |
MARSL |
Survie globale |
12 |
2274 |
S HR = 0,78 (0,71 - 0,86) |
|
Chimiothérapie radiosensibilisatrice
ajoutée à la radiothérapie radicale |
|||||
|
Sculier, 2001 (6) |
MARSL |
Survie globale |
8 |
1360 |
S HR = 0,79 (0,70 – 0,89) |
|
Rakovitch,
2004 (7) |
MAI |
Survie à 1, 2, 3 ans |
10 |
1802 |
S RR (hebdomadaire) = 0,92, (0,85 – 1,00) ; RR (quotidien) = 0,93 (0,87 – 0,99) |
|
Radiochimiothérapie concomitante versus séquentielle |
|||||
|
Aupérin, 2010 (8) |
MADI |
Survie globale |
7 |
1205 |
S HR = 0,84 (0,75 – 0,95) |
|
Radiothérapie accélérée ou
hyperfractionnée versus conventionnelle |
|||||
|
Mauguen, 2012 (9) |
MADI |
Survie globale |
10 |
2000 |
S HR = 0,88 (0,80 – 0,97) |
Références
(1) Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995 Oct 7;311(7010):899-909.
(2) Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 1995 Aug 15;76(4):593-601.
(3) Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis [published erratum appears in Ann Intern Med 1997 Apr 15;126(8):670]. Ann Intern Med 1996 Nov 1;125(9):723-9.
(4) Auperin A, Le PC, Pignon JP, Koning C, Jeremic B, Clamon G, et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients. Ann Oncol 2006 Mar;17(3):473-83.
(5) Bozcuk H, Artac M, Ozdogan M. Correlates of benefit from neoadjuvant chemotherapy before radiotherapy in non-small cell lung cancer: a meta-analytical approach with meta-regression analysis. J BUON 2010 Jan;15(1):43-50.
(6) Sculier JP, Berghmans T, Paesmans M, Branle F, Lemaitre F, Mascaux C, et al. La place de la chimiothérapie dans le traitement des cancers bronchiques non à petites cellules non métastatiques. [The role of chemotherapy in the treatment of non-metastatic, non-small cell bronchial cancers]. Rev Med Brux 2001 Dec;22(6):477-87.
(7) Rakovitch E, Tsao M, Ung Y, Pignol JP, Cheung P, Chow E. Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non-small-cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys 2004 Jan 1;58(1):196-203.
(8) Aupérin A, Le PC, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010 May 1;28(13):2181-90.
(9) Mauguen A, Le PC, Saunders MI, Schild SE, Turrisi AT, Baumann M, et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol 2012 Aug 1;30(22):2788-97.